Immunotherapy Combo Reduces Risk of Cancer Recurrence in Early-Stage Liver Cancer
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
The approval for Idacio was based on a review of data that showed similar pharmacokinetics, efficacy, safety, and immunogenicity to the reference adalimumab product.
Investigators characterized the toxicity of stereotactic body radiotherapy for oligometastases from predominantly prostate, colorectal, breast, and lung cancer.
The approval was based on data from the open-label, single-arm phase 2b TAS-120-101 trial.
Vegzelma is a vascular endothelial growth factor inhibitor.
The approval was based on data from the phase 3 TOPAZ-1 trial.
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
The application is supported by data from the two phase 3 induction studies, U-EXCEED and U-EXCEL, and one phase 3 maintenance study, U-ENDURE.
The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study.
Direct inhibition of STAT3 signaling by TTI-101 is expected to lead to reduced tumor growth.